Controversies in the Treatment of Peripheral T-cell Lymphoma.
Bachy EHospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France.
Broccoli AInstitute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
Dearden CThe Royal Marsden NHS Foundation Trust and Biomedical Research Centre, Downs Road Sutton, Surrey SM2 5PT, United Kingdom.
de Leval LInstitute of Pathology, Lausanne University Hospital and University of Lausanne, Switzerland.
Gaulard PDepartment of Pathology, Henri Mondor Hospital, AP-HP, INSERM U955, University Paris East, Créteil, France.
Koch RDepartment of Hematology and Medical Oncology, University Medical Center Gottingen, Germany.
Morschhauser FUniversité Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.
English
Peripheral T-cell lymphomas are a heterogeneous group of rare diseases with an aggressive behavior and dismal prognosis. Their classification is complex and still evolving, and several biomolecular markers now help refine the prognosis of specific disease entities, although still have limited impact in tailoring the treatment. First-line treatment strategies can cure only a minority of patients and relapsed-refractory disease still represents the major cause of failure. Frontline autologous transplantation may have an impact in the consolidation of response; however, its role is still questioned as far as complete responses obtained after induction chemotherapy are concerned. Newer drugs are now being evaluated in clinical trials, but effective salvage strategies for those who experience treatment failures are lacking. Here we review and discuss the most controversial aspects of diagnosis and treatment of peripheral T-cell lymphomas.